Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

1.

A Fluorescence-Based Assay for Proteinuria Screening in Larval Zebrafish (Danio rerio).

Hanke N, King BL, Vaske B, Haller H, Schiffer M.

Zebrafish. 2015 Jun 30. [Epub ahead of print]

PMID:
26125680
2.

Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice.

Adam O, Zimmer C, Hanke N, Hartmann RW, Klemmer B, Böhm M, Laufs U.

J Mol Cell Cardiol. 2015 Jun 3;85:140-150. doi: 10.1016/j.yjmcc.2015.05.019. [Epub ahead of print]

PMID:
26047574
3.

Evaluation of cardiovascular changes in dogs administered three positive controls using jacketed external telemetry-blood pressure (JET-BP).

Kremer JJ, Bills AJ, Hanke NJ, Chen H, Meier WA, Osinski MA, Foley CM.

J Pharmacol Toxicol Methods. 2015 May 20. pii: S1056-8719(15)00064-7. doi: 10.1016/j.vascn.2015.05.008. [Epub ahead of print]

PMID:
26001324
4.

Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models.

Schiffer M, Teng B, Gu C, Shchedrina VA, Kasaikina M, Pham VA, Hanke N, Rong S, Gueler F, Schroder P, Tossidou I, Park JK, Staggs L, Haller H, Erschow S, Hilfiker-Kleiner D, Wei C, Chen C, Tardi N, Hakroush S, Selig MK, Vasilyev A, Merscher S, Reiser J, Sever S.

Nat Med. 2015 Jun;21(6):601-9. doi: 10.1038/nm.3843. Epub 2015 May 11.

PMID:
25962121
5.

Functional MRI detects perfusion impairment in renal allografts with delayed graft function.

Hueper K, Gueler F, Bräsen JH, Gutberlet M, Jang MS, Lehner F, Richter N, Hanke N, Peperhove M, Martirosian P, Tewes S, Vo Chieu VD, Großhennig A, Haller H, Wacker F, Gwinner W, Hartung D.

Am J Physiol Renal Physiol. 2015 Jun 15;308(12):F1444-51. doi: 10.1152/ajprenal.00064.2015. Epub 2015 Apr 29.

PMID:
25925250
6.

The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines.

Malm SW, Hanke NT, Gill A, Carbajal L, Baker AF.

J Exp Clin Cancer Res. 2015 Apr 1;34:31. doi: 10.1186/s13046-015-0147-4.

7.

Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.

Hu Q, Kunde J, Hanke N, Hartmann RW.

Eur J Med Chem. 2015 May 26;96:139-50. doi: 10.1016/j.ejmech.2015.04.013. Epub 2015 Apr 8.

PMID:
25874338
8.

Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.

Baker AF, Hanke NT, Sands BJ, Carbajal L, Anderl JL, Garland LL.

J Exp Clin Cancer Res. 2014 Dec;33:111. doi: 10.1186/s13046-014-0111-8. Epub 2014 Dec 31.

9.

Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.

Baker AF, Hanke NT, Sands BJ, Carbajal L, Anderl JL, Garland LL.

J Exp Clin Cancer Res. 2014 Dec 31;33:111. doi: 10.1186/s13046-014-0111-8.

10.

Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.

Baker AF, Hanke NT, Sands BJ, Carbajal L, Anderl JL, Garland LL.

J Exp Clin Cancer Res. 2014 Dec 31;33(1):778. [Epub ahead of print]

11.

Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.

Stefanachi A, Hanke N, Pisani L, Leonetti F, Nicolotti O, Catto M, Cellamare S, Hartmann RW, Carotti A.

Eur J Med Chem. 2015 Jan 7;89:106-14. doi: 10.1016/j.ejmech.2014.10.021. Epub 2014 Oct 13.

PMID:
25462231
12.

Metabolic stability optimization and metabolite identification of 2,5-thiophene amide 17β-hydroxysteroid dehydrogenase type 2 inhibitors.

Gargano EM, Perspicace E, Hanke N, Carotti A, Marchais-Oberwinkler S, Hartmann RW.

Eur J Med Chem. 2014 Nov 24;87:203-19. doi: 10.1016/j.ejmech.2014.09.061. Epub 2014 Sep 20.

PMID:
25259513
13.

Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.

Zhu W, Hu Q, Hanke N, van Koppen CJ, Hartmann RW.

J Med Chem. 2014 Sep 25;57(18):7811-7. doi: 10.1021/jm501004t. Epub 2014 Sep 8.

PMID:
25176013
14.

Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.

Perspicace E, Cozzoli L, Gargano EM, Hanke N, Carotti A, Hartmann RW, Marchais-Oberwinkler S.

Eur J Med Chem. 2014 Aug 18;83:317-37. doi: 10.1016/j.ejmech.2014.06.036. Epub 2014 Jun 17.

PMID:
24974351
15.

Inhibition of 17β-HSD1: SAR of bicyclic substituted hydroxyphenylmethanones and discovery of new potent inhibitors with thioether linker.

Abdelsamie AS, Bey E, Hanke N, Empting M, Hartmann RW, Frotscher M.

Eur J Med Chem. 2014 Jul 23;82:394-406. doi: 10.1016/j.ejmech.2014.05.074. Epub 2014 Jun 3.

PMID:
24929290
16.

PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15.

Hanke NT, LaCasse CJ, Larmonier CB, Alizadeh D, Trad M, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N.

Eur J Immunol. 2014 Aug;44(8):2489-99. doi: 10.1002/eji.201343803. Epub 2014 May 23.

PMID:
24777831
17.

Mutations in the gene that encodes the F-actin binding protein anillin cause FSGS.

Gbadegesin RA, Hall G, Adeyemo A, Hanke N, Tossidou I, Burchette J, Wu G, Homstad A, Sparks MA, Gomez J, Jiang R, Alonso A, Lavin P, Conlon P, Korstanje R, Stander MC, Shamsan G, Barua M, Spurney R, Singhal PC, Kopp JB, Haller H, Howell D, Pollak MR, Shaw AS, Schiffer M, Winn MP.

J Am Soc Nephrol. 2014 Sep;25(9):1991-2002. doi: 10.1681/ASN.2013090976. Epub 2014 Mar 27.

PMID:
24676636
18.

Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.

Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N.

Cancer Res. 2014 Jan 1;74(1):104-18. doi: 10.1158/0008-5472.CAN-13-1545. Epub 2013 Nov 6.

19.

"Zebrafishing" for novel genes relevant to the glomerular filtration barrier.

Hanke N, Staggs L, Schroder P, Litteral J, Fleig S, Kaufeld J, Pauli C, Haller H, Schiffer M.

Biomed Res Int. 2013;2013:658270. doi: 10.1155/2013/658270. Epub 2013 Sep 11. Review.

20.

Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors.

Ferlin MG, Carta D, Bortolozzi R, Ghodsi R, Chimento A, Pezzi V, Moro S, Hanke N, Hartmann RW, Basso G, Viola G.

J Med Chem. 2013 Oct 10;56(19):7536-51. doi: 10.1021/jm400377z. Epub 2013 Sep 27.

PMID:
24025069
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk